对于社保基金，本期较上一季未再披露的社保基金共计1个，即全国社保基金五零一组合。 以上内容与数据，与有连云立场无关，不构成投资建议。据此操作，风险自担。 2025年8月20日，盟科药业(688373.SH)发布2025年半年度报告。截至2025年8月19日，共有13个机构投 资者披露持有盟科药业A股股份，合计持股量达3.31亿股，占盟科药业总股本的50.51%。其中，前十大 机构投资者包括Genie Pharma、MicuRx (HK) Limited、Best Idea International Limited、JSR Limited、GP TMT Holdings Limited、华盖资本有限责任公司-北京华盖信诚远航医疗产业投资合伙企业(有限合伙)、 新沂优迈科斯财务咨询中心(有限合伙)、浙江华海药业股份有限公司、南京同兴赢典私募基金管理有限 公司-南京同兴赢典壹号投资管理中心(有限合伙)、中泰创业投资(上海)有限公司，前十大机构投资者合 计持股比例达48.49%。相较于上一季度，前十大机构持股比例合计下跌了1.07个百分点。 公募基金方面，本期较上一季未再披露的公募基金共计2个，包括汇添富医疗服务灵 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 近日，根据国家药品监督管理局药品审评中心（以下简称"CDE"）发布的公示信息，浙江华海药业股份 有限公司（以下简称"华海药业"或"公司"）下属子公司上海华奥泰生物药业股份有限公司（以下简 称"华奥泰"）自主研发的瑞西奇拜单抗（研发代号为：HB0034）注射液被纳入优先审评审批程序的品 种名单。根据《国家药监局关于发布突破性治疗药物审评工作程序（试行）等三个文件的公告》（2020 年第82号）有关要求，CDE对纳入优先审评审批程序的药品上市许可申请，按注册申请受理时间顺序优 先配置资源进行审评。现将相关情况公告如下： 一、药物基本情况 药物名称：瑞西奇拜单抗注射液 剂型：注射剂 拟定适应症：用于治疗成人泛发性脓疱型银屑病（GPP）发作 注册分类：治疗用生物制品1类 申请人：上海华奥泰生物药业股份有限公司 优先审评理由：本品符合《药品注册管理办法》和《国家药监局关于发布突破性治疗药物审评工作程序 （试行）等三个文件的公告》（20 ...

Group 1: Core Insights - The Taizhou Bay Economic and Technological Development Zone's pharmaceutical park is a national pilot for pollution reduction and carbon emission control, implementing 20 green low-carbon technology transformation projects and achieving a carbon reduction of approximately 12,500 tons [1] - The park has established a complete industrial chain from intermediates to active pharmaceutical ingredients (APIs) and formulations, aiming to become a globally influential pharmaceutical innovation hub [2] - The transition from "pharmaceutical chemistry" to "pharmaceutical health" is a key path for industrial upgrading, with a focus on traditional pharmaceutical industries transforming into new materials and high-end formulations [2] Group 2: Technological Innovations - Huahai Pharmaceutical's Sichuan branch has achieved a 40% reduction in carbon emissions per unit output from 0.91 tons per 10,000 yuan in 2020 to 0.54 tons per 10,000 yuan in 2024, alongside significant waste reduction and economic benefits [3] - The company has implemented advanced solvent recovery technologies to improve energy efficiency and reduce steam and electricity consumption by 30% and 17% respectively [3] - A unique evaluation index for pollution reduction and carbon emission control in the pharmaceutical industry has been established, reflecting the levels of "pollution reduction," "carbon reduction," and "efficiency increase" [3] Group 3: Digital Empowerment - The Taizhou Bay Economic and Technological Development Zone has invested 100 million yuan in a "smart park" regulatory platform, integrating AI and big data for environmental management [4] - The park has developed a comprehensive ecological monitoring network that covers environmental quality, pollution sources, and ecological conditions [5] - The park has been recognized as a national pilot for innovative collaborative pollution reduction and carbon emission control, and has achieved the status of a "zero direct discharge" industrial park in Zhejiang Province [5]

Core Viewpoint - Qilu Pharmaceutical's application for the marketing authorization of phospho-lusatinib tablets has been accepted, marking its entry into the competitive landscape of domestic generics for this drug, which has a projected global sales exceeding $4.7 billion in 2024 [1][4]. Group 1: Market Performance and Sales Data - Phospho-lusatinib, a first-in-class JAK1/JAK2 inhibitor, has shown impressive market performance since its launch, with global sales reaching nearly $4 billion in 2022 and increasing to approximately $4.314 billion in 2023, with a forecasted rise to $4.728 billion in 2024 [4][7]. - In China, the sales of phospho-lusatinib exceeded 200 million yuan in 2020, growing to 553 million yuan in 2023, and expected to increase by 16.11% to 642 million yuan in 2024 [7]. Group 2: Competitive Landscape - Qilu Pharmaceutical is competing with other companies, including Chengdu Yuandong Biological and 19 other firms, in the race to become the second domestic producer of phospho-lusatinib, with multiple applications currently under review [13][19]. - Chengdu Yuandong Biological has already secured the first generic approval for phospho-lusatinib, indicating a competitive environment for Qilu Pharmaceutical's application [11]. Group 3: Patent and Regulatory Information - The patent for phospho-lusatinib is protected until June 12, 2028, with several patents granted in China and other regions, which may impact the competitive landscape for generics [9][10]. - Qilu Pharmaceutical's previous application for the same product was not approved, highlighting the challenges in the regulatory process [17].

每经AI快讯，8月18日，华海药业(600521.SH)公告称，公司下属子公司华奥泰自主研发的瑞西奇拜单抗 （研发代号为：HB0034）注射液被纳入优先审评审批程序的品种名单。该药物用于治疗成人泛发性脓 疱型银屑病（GPP）发作，属于治疗用生物制品1类。目前全球范围内，尚未有国内企业自研的靶向IL- 36R抗体获批上市。HB0034作为国内首个自研创新抗IL-36R抗体，可通过抑制IL-36通路发挥抗炎的生 物学效应。 ...

| 股票简称：华海药业 | 股票代码：600521 | 公告编号：临 2025-090 | | --- | --- | --- | | | | 号 | | 债券简称：华海转债 | 债券代码：110076 | | 关于下属子公司产品被纳入优先审评品种名单的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，根据国家药品监督管理局药品审评中心（以下简称"CDE"）发布的公示 信息，浙江华海药业股份有限公司（以下简称"华海药业"或"公司"）下属子公司 上海华奥泰生物药业股份有限公司（以下简称"华奥泰"）自主研发的瑞西奇拜单抗 （研发代号为：HB0034）注射液被纳入优先审评审批程序的品种名单。根据《国家 药监局关于发布突破性治疗药物审评工作程序（试行）等三个文件的公告》（2020 年 第 82 号）有关要求，CDE 对纳入优先审评审批程序的药品上市许可申请，按注册申 请受理时间顺序优先配置资源进行审评。现将相关情况公告如下： 一、药物基本情况 药物名称：瑞西奇拜单抗注射液 剂型：注射剂 拟定适应症：用于治疗成人泛发性脓 ...

台州市市值最高的十家上市公司（2025年5月） 10 、杰克股份 市值185.18亿元，总部椒江区，第一大股东 台州市杰克商贸有限公司。 9、 银轮股份市值 207.86 亿元，总部天台县 ，第一大股东徐小敏 。 8、 航天彩虹市值 215.61 亿元，总部台州湾集聚区，第一大股东 中国航天空气动力技术研究院 。 7 、利欧股份市值 245.14亿元，总部 温岭市 ，第一大股东王相荣 。 6 、水晶光电市值 252.82亿元， 总部椒江区 ，第一大股东星星集团。 5、 华海药业市值 260.72亿元， 总部临海市，第一大股东 陈保华 。 4 、双环传动市值 269.79 亿元，总部玉环市 ，第一大股东香港中央结算有限公司 。 3、 天山铝业 市值358.66 亿元，总部温岭市 ，第一大股东上海天铝申锟矿业科技有限公司 。 2、 苏泊尔市值 435.22 亿元，总部玉环市 ，第一大股东苏显泽 1、 古茗市值 626.65 亿元，总部温岭市，第一大股东 王云安。 台州市上市公司市值排行榜(2025年5月) 公司总部 序号 公司名称向值(亿元) 第一大股东 杰克股份 阮积祥 台州市杰克商贸有限公司 10 185. ...

Core Viewpoint - The article highlights the recent completion of nearly 100 million yuan in Pre-A round financing for Libo Bio, led by Tianshili Capital and Panlin Capital, showcasing the growing interest in biotech startups and the trend of venture capitalists seeking projects in research-intensive areas [2][9]. Group 1: Company Overview - Libo Bio was established in September 2022 by a team of three scientists, including Zhou Yaoqi, Zhan Jian, and Fang Chao, and initially received angel round financing from Sequoia China and Innovation Works [3][9]. - The company focuses on RNA research, leveraging AI to discover stable tertiary structures within RNA and predict their folding shapes and small molecule binding pockets [8][9]. - The founding team has extensive experience, with Zhou Yaoqi having nearly 30 years in structural computation, Zhan Jian being a core inventor of RNA stability methods, and Fang Chao specializing in small molecule drug development [6][9]. Group 2: Investment and Financing - The recent Pre-A round financing of nearly 100 million yuan was supported by Tianshili Capital and Panlin Capital, with follow-on investments from Yuan Sheng Venture Capital and other funds [2][9]. - The financing is seen as a significant step in transforming cutting-edge research into new productive forces, as emphasized by Yan Ning, the director of Shenzhen Bay Laboratory [5][6]. Group 3: Industry Trends - The article reflects a broader trend in the venture capital landscape, where investors are increasingly targeting projects in research-heavy environments, particularly those associated with prestigious research institutions [4][9]. - The success of Libo Bio exemplifies the effective transition from laboratory research to clinical applications, aligning with Shenzhen's efforts to promote the commercialization of frontier research [5][6].

Core Points - The fourth Synthetic Biology and Green Bio-Manufacturing Conference (SynBioCon 2025) will focus on four main directions: AI + Bio-Manufacturing, Green Chemistry and New Materials, Future Food, and Future Agriculture [2] - The conference will take place from August 20 to 22, 2025, at the Sheraton Hotel in Donggang, Ningbo, Zhejiang [2][3] - Various activities will be held concurrently, including a Youth Forum on Bio-Manufacturing, a high-level discussion on the bio-manufacturing industry, and a closed-door seminar on the "2025 AI Empowering Bio-Manufacturing Industry Innovation Development Blue Book" [2][3] Event Details - Registration will occur on August 20 from 12:00 to 20:00 and on August 21 from 8:50 to 12:00, where attendees will receive conference materials [7] - The conference venue is the Sheraton Hotel, located 17.5 km from Ningbo Lishe International Airport and 4.5 km from Ningbo Railway Station [8] - Accommodation options include the Sheraton Hotel at a rate of 400 RMB per night and the Portman Hotel at 320 RMB per night, both including breakfast [9] Agenda Highlights - The conference will feature a macro forum on the bio-manufacturing industry on August 21, followed by specialized forums on Green Chemistry and New Materials, AI applications in bio-manufacturing, and Future Food & Agriculture [11][20] - Notable sessions include discussions on bio-based carboxylic acids, enzyme molecular engineering, and the design of microbial cell factories for green bio-manufacturing [17][25] Supporting Organizations - The conference is organized by Ningbo Detai Zhongyan Information Technology Co., Ltd. and supported by various institutions, including Peking University Ningbo Institute of Ocean Medicine and the China Society of Biotechnology [4][5] - Strategic media partners and numerous industry experts will also participate, enhancing the conference's profile and outreach [5][31] Networking Opportunities - The event will provide ample networking opportunities through various forums and discussions, allowing industry leaders and researchers to connect and share insights [14][31] - A list of participating organizations and their representatives has been compiled, showcasing a diverse range of expertise in the bio-manufacturing sector [45][46] Innovation Showcase - The conference will feature a showcase of synthetic biology technology achievements, including projects on functional sugars, microalgae-based selenium proteins, and the bio-manufacturing of natural terpenes [42][43][44] - These innovations highlight the potential of synthetic biology in addressing contemporary challenges in food, health, and environmental sustainability [42][43]

Core Insights - Avermectins are among the most widely used drugs globally, with a market size of $1.371 billion in 2024. The demand for new types of avermectins, such as Ivermectin and Doramectin, is rapidly increasing, with market sizes projected at $3.33 billion and $134 million respectively in 2024 [2][3]. - China's biomanufacturing level for avermectins, particularly for new generics like Ivermectin and Doramectin, has been lagging behind international original research enterprises [2]. - The Microbial Research Institute has successfully enhanced the biomanufacturing yield of avermectins to 9.3 g/L, establishing a significant technological advantage in this field [2]. Group 1 - The Baiweimectin component, developed by a collaborative team, exhibits superior nematicidal activity and has achieved a fermentation yield of 8.4 g/L [3][5]. - A universal reprogramming engineering strategy was developed, which includes a dynamic control system for Streptomyces species, facilitating the efficient production of Baiweimectin [3]. - The technology developed will provide core support for the efficient biomanufacturing of Streptomyces-derived drugs [3]. Group 2 - The economic loss caused by nematode diseases in China reaches up to 80 billion yuan annually, highlighting the importance of Baiweimectin as a biopesticide with independent intellectual property rights [5]. - Baiweimectin is currently undergoing simultaneous pesticide registration applications both domestically and internationally [5]. Group 3 - The fourth Synthetic Biology and Green Biomanufacturing Conference (SynBioCon 2025) will focus on AI in biomanufacturing, green chemicals, new materials, future food, and agriculture [7]. - The conference will feature various activities, including a youth forum and a closed-door seminar on the innovation development blue book for AI-enabled biomanufacturing [7].